Cargando…
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
BACKGROUND: Controlled studies and observational studies have shown that sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for the survival of patients with heart failure (HF). However, it is unclear whether SGLT-2i can provide benefit in patients with other cardiovascular dise...
Autores principales: | Zheng, Caiyun, Lin, Meimei, Chen, Yan, Xu, Haiting, Yan, Lingqun, Dai, Hengfen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063441/ https://www.ncbi.nlm.nih.gov/pubmed/33888126 http://dx.doi.org/10.1186/s12933-021-01272-z |
Ejemplares similares
-
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018) -
Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis
por: Bhattarai, Mukul, et al.
Publicado: (2022) -
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020) -
Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
por: Chen, Lu, et al.
Publicado: (2020) -
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)